RADX and RAD Related Headlines
Go Back- Radiopharm Theranostics doses first patient in cancer drug trial
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics gets approval for prostate cancer drug trial
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics advances to third cohort in cancer drug trial
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
- Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
- Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
- Radiopharm gets approval to raise dose in cancer drug trial
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
- Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
- Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
- Radiopharm Theranostics adds cancer specialist to scientific advisory board
- Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
- Radiopharm Theranostics (RADX) and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
- Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
- Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
RADX and RAD Related Press Releases
Go Back- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
- Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
- Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
- Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
- Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
- Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
- Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
- Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
